Shigella vaccine - China National Biotec Group
Latest Information Update: 31 Oct 2021
At a glance
- Originator China National Biotec Group
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Shigella infections
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Shigella-infections in China (Parenteral)
- 19 Jan 2016 Clinical trials in Shigella infections in China (Parenteral) prior to January 2016